Royal Bank Of Canada Issues Positive Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price

Intellia Therapeutics (NASDAQ:NTLA) had its price target boosted by Royal Bank Of Canada from $9.00 to $15.00 in a report issued on Tuesday morning,Benzinga reports. Royal Bank Of Canada currently has a sector perform rating on the stock.

Several other research analysts also recently issued reports on the company. Wolfe Research reaffirmed a “peer perform” rating on shares of Intellia Therapeutics in a research note on Wednesday, November 12th. JPMorgan Chase & Co. restated an “underweight” rating and set a $5.00 target price (down from $12.00) on shares of Intellia Therapeutics in a report on Friday, November 7th. HC Wainwright lifted their target price on shares of Intellia Therapeutics from $25.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday. Wedbush lowered their price target on shares of Intellia Therapeutics from $9.00 to $7.00 and set a “neutral” rating on the stock in a research report on Friday, November 7th. Finally, Oppenheimer set a $27.00 price objective on shares of Intellia Therapeutics in a research note on Friday, November 7th. Ten equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $19.14.

Intellia Therapeutics Price Performance

Shares of NASDAQ:NTLA opened at $13.60 on Tuesday. The firm has a market capitalization of $1.61 billion, a price-to-earnings ratio of -3.55 and a beta of 2.10. The business’s 50 day simple moving average is $12.09 and its 200-day simple moving average is $13.10. Intellia Therapeutics has a 12 month low of $5.90 and a 12 month high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($0.99) by $0.16. The firm had revenue of $23.02 million during the quarter, compared to the consensus estimate of $12.17 million. Intellia Therapeutics had a negative return on equity of 56.81% and a negative net margin of 609.85%.Intellia Therapeutics’s quarterly revenue was up 78.4% on a year-over-year basis. During the same period last year, the business posted ($1.27) EPS. On average, equities analysts anticipate that Intellia Therapeutics will post -5.07 earnings per share for the current year.

Insider Activity at Intellia Therapeutics

In other Intellia Therapeutics news, EVP Birgit C. Schultes sold 8,508 shares of the business’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $78,358.68. Following the completion of the transaction, the executive vice president directly owned 98,533 shares in the company, valued at approximately $907,488.93. The trade was a 7.95% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP James Basta sold 10,397 shares of the firm’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $95,756.37. Following the sale, the executive vice president owned 101,528 shares in the company, valued at $935,072.88. This trade represents a 9.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 53,051 shares of company stock valued at $488,600. Company insiders own 3.10% of the company’s stock.

Hedge Funds Weigh In On Intellia Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Comerica Bank grew its holdings in Intellia Therapeutics by 45.8% in the 4th quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after buying an additional 901 shares during the period. Headlands Technologies LLC acquired a new stake in shares of Intellia Therapeutics in the second quarter worth approximately $26,000. Blue Bell Private Wealth Management LLC acquired a new stake in shares of Intellia Therapeutics in the third quarter worth approximately $30,000. Caitong International Asset Management Co. Ltd purchased a new stake in Intellia Therapeutics in the third quarter valued at approximately $30,000. Finally, Advisory Services Network LLC acquired a new position in Intellia Therapeutics during the third quarter worth approximately $33,000. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Intellia Therapeutics

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: FDA removed the clinical hold on Intellia’s MAGNITUDE Phase 3 / heart‑disease gene therapy program — a major regulatory clearing event that had already pushed the stock higher. US FDA lifts clinical hold on Intellia’s heart disease gene therapy trial
• Positive Sentiment: Several brokers raised ratings/price targets (William Blair upgraded to Outperform; HC Wainwright, Citizens JMP and Leerink raised price targets), signaling improving analyst sentiment and potential re‑rating upside. Intellia Therapeutics (NASDAQ:NTLA) Upgraded by William Blair to “Outperform” Rating Analyst price target changes
• Positive Sentiment: Notable institutional/big‑name interest: Cathie Wood’s ARK (coverage article) is buying depressed growth names, which can attract investor attention and flows into beaten‑down biotech names. Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
• Neutral Sentiment: Company presented longer‑term clinical data for lonvo‑z at AAAAI (three‑year follow‑up and patient‑focused research) — supportive but not an immediate regulatory catalyst. Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z)
• Neutral Sentiment: Smaller price‑target increases from RBC and Wells Fargo to $15 provide modest near‑term support but signal only limited upside vs. some higher analyst targets. RBC & Wells Fargo PT raises
• Negative Sentiment: Canaccord trimmed its price target from $54 to $48 (still a Buy) — a reduction in optimism that could weigh on sentiment given prior higher targets and the stock’s recent run. Canaccord lowers price target

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.